Hepatitis B virus genotypes and evolutionary profiles from blood donors from the northwest region of China

1743-422X-6-199 1743-422X Research Hepatitis B virus genotypes and evolutionary profiles from blood donors from the northwest region of China Hu Xing-bin hxbyqh@fmmu.edu.cn Yue Qiao-hong hxbyqh@163.com Zhang Xian-qing Zhangxq@fmmu.edu.cn Xu Xue-qing buyi_chu@gmail.com Wen Yin yinwen@fmmu.edu.cn Chen Yao-zhen chenyz@fmmu.edu.cn Cheng Xiao-dong chengxd@fmmu.edu.cn Yang Liu yangliu@fmmu.edu.cn Mu Shi-jie musj1963@fmmu.edu.cn

Department of Blood Transfusion, Xijing Hospital, the Fourth Military Medical University, 17th Changlexi Road, Xi'an 710032, PR China

Department of Clinic Molecular Research Center & Clinic Diagnostic Laboratory, Xijing Hospital, Fourth Military Medical University, 17th Changlexi Road, Xi'an 710032, PR China

Department of Molecular Genetics, Third Military Medical University, Gaotanyan, Chongqing, 40038, PR China

Department of Electron Microscope, Centralab, Fourth Military Medical University, 15th Changlexi Road, Xi'an 710032, PR China

Virology Journal 1743-422X 2009 6 1 199 http://www.virologyj.com/content/6/1/199 10.1186/1743-422X-6-199 19917138 21 7 2009 17 11 2009 17 11 2009 2009 Hu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Hepatitis B virus (HBV) is prevalent in China and screening of blood donors is mandatory. Up to now, ELISA has been universally used by the China blood bank. However, this strategy has sometimes failed due to the high frequency of nucleoside acid mutations. Understanding HBV evolution and strain diversity could help devise a better screening system for blood donors. However, this kind of information in China, especially in the northwest region, is lacking. In the present study, serological markers and the HBV DNA load of 11 samples from blood donor candidates from northwest China were determined. The HBV strains were most clustered into B and C genotypes and could not be clustered into similar types from reference sequences. Subsequent testing showed liver function impairment and increasing virus load in the positive donors. This HBV evolutionary data for China will allow for better ELISA and NAT screening efficiency in the blood bank of China, especially in the northwest region.

Introduction

Hepatitis B virus (HBV) poses a great threat to humans, with serious consequences including liver cirrhosis, hepatocellular carcinoma and polyarteritis nodosa 1. This infection is prevalent in Asia, Africa, Southern Europe and Latin America 2. Roughly 2 billion people, one-third of the world's population, have serological evidence of past or ongoing infection with HBV. Approximately 5-10% of infected adults and 80-90% of children become chronic carriers of HBV 34. China has been heavily affected over a considerable period of time; consequently about 10% of the population are carriers or sufferers 5.

Because of the high prevalence of HBV, the blood bank of China must screen donors for HBV infection 6. All samples from blood donors are tested for HBV surface antigen (HBsAg) and alanine amino transferase (ALT). HBsAg is currently identified by ELISA, and ALT is tested for using dynamic enzyme methods. Undoubtedly, such screening is instrumental in reducing the risk of HBV transmission through blood transfusion 7. However, as mutations can occur in different viral stains, ELISA occasionally fails to detect HBV-infected donors 891011.

DNA tests have revealed that HBV strains from blood donors vary in different geographical areas. Occult HBV infection, which threatens the safety of blood transfusion, is linked at least in part to the genetic distance of the viral strains 12. Nucleic acid testing (NAT) for HBV in a large number of blood donors has identified HBV DNA-positive but HBsAg-negative donors, providing a unique opportunity to investigate HBV infection in more detail 1314.

Although the DNA test is superior to ELISA and can overcome some of its disadvantages, in China the higher cost and imperfect protocols have prevented widespread use. Consequently, until now, ELISA has remained the major testing method in China. To improve HBsAg testing, it is necessary to probe HBV virus evolution, because evolutionary analysis will help to promote ELISA innovations 15. However, data about HBV evolution in Chinese donors, especially in the northwest region of China, is not yet available, creating a hurdle for the development of more efficient testing.

Here we reported that 11 HBV strains from northwest China blood donor candidates were mostly clustered into B and C genotypes. These pathogens, which appear to have developed from a common parent, could not be clustered into similar genotypes from the reference sequences. This points to a high mutation frequency of HBV. Follow-up testing showed liver function impairment and increased virus load in these positive donors. Our research has supplied HBV evolution data and will pave the way for improving ELISA and NAT screening in the blood bank of China.

Materials and methods

Blood donor recruitment and sample collection

120 donors, negative for anti-HCV and anti-HIV antibodies, were analyzed. All recruited donors were unremunerated volunteers from either urban or rural areas. They were medically assessed and via a questionnaire denied any known risk factors for viral infection. Donors found to be HBV carriers were also asked to give follow-up blood samples for further study. The study was approved by the Ethics Committee of Fourth Military Medical University and written informed consent was obtained from the participants.

HBV serological marker determination

Testing for HBV serological markers, including HBs, anti-HBs, anti-HBe, HBe and anti-HBs, were performed by ELISA using an automatic enzyme detection system (Tecan, Swiss) and a commercial kit (InTec Products, China) according to the manufacturers' protocols. For the quantitative detection of the markers, serum from blood donors was applied to AXSYM MEIA (Abbott Diagnostics, Germany). To measure the ALT level, serum was separated and run through an automatic biochemistry analyzer (Hitachi, Japan) using Kit (Shanghai Fousun Long March Medical Scince.Co.Ltd. China).

2.3 DNA analysis

NAT was adapted for the current study as previously described 16. Briefly, 120 donor blood samples were divided into 10 pools with 12 samples each pool. DNA from the blood samples was extracted according the manufacturer's protocol (Qiagen, Germany) and mixed 16. Real-time PCR was used to detect HBV in each pool, following the manufacturer's instructions (Qiagen, Germany). If a positive reaction was observed, the pool was divided into 6 samples and real-time PCR was repeated. If there was a second positive test, each individual sample was tested. After that, quantitive PCR was employed for to quantify viral load.

As Katsoulidou et al. described 17, positive samples were genotyped using nest-PCR. Briefly, the first-round PCR primers (outer primer pairs) and second-round PCR primers (inner primer pairs) were designed on the basis of the conserved nature of nucleotide sequences in the regions of the pre-S1 through S genes. At the end, agar electrophoresis was employed to discern genotype.

11 HBV DNA reactive samples were randomly picked out (hereafter referred to as donors 1 to 11). From these samples, HBV DNA was extracted from 1.0 mL of serum using a kit (Qiagen GmbH, Germany), according to the manufacturer's instructions. Then, sequence analysis, beginning from the S region of HBV genome, was performed by an external company (Sunbiotech. Ltd China) using an ABI sequencing system.

Phylogenetic analysis

HBV genome phylogenetic analysis was performed by multiple sequence alignment using the ClustalW v1.83 program 18. For this purpose, HBV sequences from the donors and reference sequences from the GenBank database http://www.ncbi.nih.gov were aligned.

Results

NAT screening of 11 HBV-infected donors

To screen the HBV-infected donors, NAT was employed based on real-time PCR. In the first round of screening, there were 6 positive pools (Fig. 1A, 60%). A single positive HBV sample was eventually identified by repeat real-time PCR. There were 12 reactive blood donors, representing about 9% of all the recruited donors.

Figure 1

NAT screening of 11 reactive samples from 120 blood donors

NAT screening of 11 reactive samples from 120 blood donors. To screen the HBV infected donors, NAT was employed. 120 donor blood samples were divided into 10 pools with 12 samples in each pool. Real-time PCR was used on each pool. If a positive reaction was observed, the pool was narrowed until a single reactive sample was detected. Quantitive PCR was then performed against positive samples. A, reactive sample counts of each pool in the first round of detection; blank represents HBV-reactive sample counts and black is the total sample counts in the pool; B, lower HBV DNA copies of reactive samples in the NAT-reactive samples; C higher HBV DNA copies of reactive samples in the NAT-reactive samples.

Next, HBV DNA load in the positive donors was measured. As shown in Figures 1B and 1C, donors 3, 4, 5 and 7 had several hundred virus copies, while donors 1,2,6,8,9,10 and 11 had lower virus loads.

The serological and personal data of the HBV DNA-reactive donors are noted in Tables 1 and 2. Consistent with virus load, donors 3, 4, 5 and 7 had higher ALT levels (Table 1 and Fig. 1C), which were all beyond the upper limit (20 IU.L^-1) for blood donors formulated by China. On the other hand, serological marker analysis of HBV in the samples showed that donors 3 and 4 were more contagiousness, as they were HBsAg, HBeAg and anti-HBc positive (Table 2). Although HBsAg in donor 6 was negative (Table 2), HBV DNA testing proved there were few virus copies (Fig. 1B).

Table 1

Data of blood donors with positive HBsAg reaction

NO.

Year

Femal/Male

ALT(U.L-¹)

Table 2

Serological markers of donors bearing HBV

NO.

HBs

Anti-HBs

HBe

Anti-HBe

Anti-HBc

Total

The major HBV strains in local donors were B and C genotypes

HBV strains vary in different regions and different strains may contribute to ELISA test failure. To further discern the HBV type in the infected samples, all 11 positive samples underwent HBV genotyping by PCR (Fig. 2A). 9 virus strains, from approximately 81% of all the positive samples, belonged to the B or C group, but 2 D genotype strains (19%) were also observed (Fig. 2B). Furthermore, the HBV DNA load in cases with the C subtype was higher than that in the B or D genotypes (Fig. 1B and 1C).

Figure 2

Genotyping of HBV reactive blood donors

Genotyping of HBV reactive blood donors. All positive samples from the blood donors were subjected to DNA extraction and then genotyping by nest-PCR. A, gel electrophoresis of PCR products after nest-PCR in genotype analysis (data represents one of three independent experiments); B, sample counts of each genotype according A.

HBV strains from local donors evolved from common parents

HBV has evolved in recent years. This evolution has resulted in blood transfusion transmission because of ELISA test failures. Since most of the HBV strains in the current study belonged to the B or C genotypes, we further sequenced the HBV-DNA positive samples to make a phylogenetic appraisal. Fortunately, all the strains were successfully sequenced. Then, a phylogenetic tree was made, joined by reference sequence from GeneBank using Clustal W 1.83 software. According to the tree, the 2 donor samples belonging to the D genotypes (donors 2 and 10) were highly homogenic, while the 4 C strains (donors 3, 4, 5 and 7) came from a common 'parent' (Fig. 3). With the 5 B strains, the situation was more complex. Although they derived from the same root, two evolutionary directions were identified. As shown in Figure 3, the virus strain from donors 1 and 8 was clustered, while the strain from donors 6, 9 and 11 belonged to another group.

On the whole, however, the strains could not be clustered into a similar subtype using reference sequences, which proves the high mutation rate of HBV.

Figure 3

Phylogenetic analysis of HBV strains from the blood donors

Phylogenetic analysis of HBV strains from the blood donors. HBV genome sequencing was carried out. Some available sequences from the GenBank database were used to construct the tree with the Clustal W v1.83 program. Figures in the lower part of the tree are the blood donors' numbers; characters in the other part of the tree are serial numbers in GeneBank; characters in the right bracket refer to HBV genotype.

Infection of HBV-positive donors worsened in the following 3 years

To monitor HBV infection after the preliminary analysis, we tracked the positive blood donors in the following years. Two years later, donor 6, who was negative reaction in the preliminary serological test, became reactive against HBsAg, while the other donors displayed increased positive markers of infection (Table 3). Repeat ALT testing showed that the liver function of these donors was, at least partly, impaired (Table 4). We noted that the level of ALT in donor 3 decreased because she received anti-viral therapy (Table 4). Virus load was serially quantitated by real-time PCR. As shown in Table 5, the number of virus copies increased in all reactive donors, except donor 3 (who was being treated). Once again, several hundred HBV copies were detected in donor 6.

Table 3

Quantitive levels of serological markers of HBV in reactive donors two years later

NO.

HBs(nq.mL^-1)

Anti-HBs

(mIU.mL^-1)

HBe

(ncuq.mL^-1)

Anti-HBe

(ncuq.mL^-1)

Anti-HBc

(ncuq.mL^-1)

donor 1

2.8

32.1

0.02

6.2

11.8

donor 2

3.1

41.0

0.08

5.9

8.3

donor 3

15.2

192.5

2.5

121.8

31.2

donor 4

19.8

288.1

10.1

117.4

15.7

donor 5

62.9

162.3

8.4

125.9

12.1

donor 6

1.9

24.2

0.01

2.7

0.9

donor 7

7.5

69.8

8.7

18.1

11.9

donor 8

12.7

32.2

0.09

7.3

7.1

donor 9

33.9

0.01

6.9

5.9

donor10

2.6

42.3

0.02

8.5

6.7

donor11

12.5

51.7

0.07

6.6

6.8

ncu: national clinical unit.

Table 4

ALT levels in the consecutive test of HBV reactive donors

Time(month)

ALT(U.L-¹)

donor 1

donor 2

donor 3

102

110

123

151

130

107

donor 4

donor 5

donor 6

donor 7

donor 8

donor 9

donor 10

donor 11

N: no test.

Table 5

Virus load in the following test of HBV reactive donors

Time(month)

Virus Copy

donor 1

6.1E1

7.9 E1

8.8 E1

10 E2

15 E3

21 E3

donor 2

2.1 E1

5.3 E1

6.7 E1

8.2 E2

11.8 E1

donor 3

2.8 E2

5.4 E2

2.3 E3

3.5 E3

1.2 E3

2.1 E3

donor 4

3.9 E2

8.3 E2

4.3 E3

7.5 E3

0.3 E4

32.0E4

donor 5

1.6 E2

44 E2

1.3 E3

4.5 E3

3.2 E4

4.9 E4

donor 6

1.2 E1

3.9 E1

6.2 E1

9.8 E2

11 E2

1.7 E3

donor 7

3.2 E2

24.1 E2

86.7 E2

2.5 E3

8.2 E3

14.1 E3

donor 8

5.7 E1

6.3 E1

7.5 E1

9.4 E2

10.1 E2

14.9 E3

donor 9

1.3 E1

4.2 E1

5.9 E1

7.2 E2

7.8 E2

9.3 E3

donor 10

8.6 E1

9.9 E1

16.7 E1

2.5 E2

5.3 E2

14.6 E2

donor 11

4.5 E1

5.6 E1

16.8 E1

4.1 E2

12.3 E2

25.3 E2

N: no test. E1:10¹; E2:10²;E3:10³;E4:10⁴.

Discussion

NAT has been globally adopted in blood banks to detect infectious pathogens, especially in developed nations 16. With a proper pool size, it can detect several virus copies in a sample. In this way, the testing window period of pathogens, which is one of the most important risk factor in transfusion medicine, can be overcome. However, due to lower numbers of virus copies during early stages of infection, NAT sometimes produces false negative results. Consequently, pool size becomes a key factor in interpreting NAT. In the current study, our NAT system could detect 10 copies of HBV. This sensitivity was enough to detect the virus in a 6-sample pool.

Other disadvantages have prevented the wider uptake of NAT 19. One complex issue is how to determine the appropriate blood donor pool size 2021. We screened 11 reactive samples from 120 blood donors using NAT. The samples were divided into 10 pools and each pool contained 12 samples. In effect, 3 real-time PCRs were run before the single reactive sample was found. If we made larger pools, perhaps more real-time PCRs would have been performed, given the high prevalence of HBV in China. We found that the test results from NAT were almost perfectly consistent with ELISA testing (9.16% V.S 8.33%, P > 0.05), although the latter failed in donor 6 due to lower HBV virus copy numbers. We therefore agree with earlier authors that ELISA can be used as the first round test and NAT in the second round analysis 22.

In 1988, Okamoto et al. categorized HBV into A, B, C and D types according the genome sequence diversity 23. There are now 8 known genotypes of HBV, from A to H, with a genome difference greater than 8% 2425. Genotypes A, B, C and D are all observed in China. Consistent with other reports, we confirmed that the B and C genotypes are the most common in China 26. Genotype of HBV is significant to prognosis and test strategy 27. We found that blood donors with the C genotype had higher virus loads and more serious liver impairment in the following years, which is consistent with the findings of other researchers 28.

According to our serological data, the 11 positive samples could be divided into two major groups: 6 subjects (54.5%) were anti-HBc positive without detectable antibodies to surface antigen, whereas 3 (27.2%) were positive for both anti-HBc and anti-HBs. These results indicate that occult HBV infection can occur in blood donors 2930. It has been reported that occult HBV infection without anti-HBs is more dangerous because cases of transmission by donations carrying anti-HBc without anti-HBs have been documented, while no evidence of transmission has been found when donors were both anti-HBc and anti-HBs reactive 3132.

Phylogenetic analysis is a method commonly used to trace virus evolution 33. With HBV, an evolutionary tree can be drawn from a partial sequence or the whole genome 34. We made a genome tree and, surprisingly, found that the strains in our region could not be clustered into similar types using reference sequences. The reason may be the high mutation rate of HBV, for which there is considerable supporting evidence 3536. However, virus subtypes B or C, which were found in the present study, are clues suggesting different evolutionary roots. We likewise did not detect recombinant HBV strains, which have occasionally been reported as intertypes 3738. Recombinant HBV strains, if present, might contribute to the diverse phylogenetic profile in our region. On the other hand, the virus strains we detected that were of the same type had clearly developed from the same progenitors, which suggested that local HBV evolution had specific characteristics. This phenomenon is relevant for both ELISA and NAT improvement.

In summary, the 11 HBV strains from northwest China blood donor candidates which we identified were mostly clustered into B and C genotypes. These organisms could not be clustered into similar types using reference sequences. Follow-up testing showed liver function impairment and increasing virus load in the positive donors. The study provides evolutionary data about HBV in China and could lead to improvements in ELISA and NAT screening efficiency in the blood bank of China.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

HXB carried out the donors secreen and drafted the manuscript. YQH participated in the sequencing. ZXQ performed NAT analysis. XXQ carried out molecular genetic studies. YW carried out genotyping. CYZ and CXD participated in the follow-up test of ALT. YL participated in the ELISA test analysis. MSJ partipated in the design of the study. All authors read and approved the final manuscript.

Acknowledgements

We are thankful for the support of the Blood Bank of Xi'an, PLA.

Preoperative vaccination for HBV at Polish hospitals as a possible public health tool to limit the spread of the epidemic: A cross-sectional study Ganczak M Szych Z Korzen M Vaccine 2009 27 3969 74 10.1016/j.vaccine.2009.04.042 19389444 Predictors of esophageal varices in patients with HBV-related cirrhosis: a retrospective study Hong WD Zhu QH Huang ZM Chen XR Jiang ZC Xu SH Jin K BMC Gastroenterol 2009 9 11 10.1186/1471-230X-9-11 2661092 19196464 Envelope protein variability among HBV-Infected asymptomatic carriers and immunized children with breakthrough infections Mendy M D'Mello F Kanellos T Oliver S Whittle H Howard CR J Med Virol 2008 80 1537 46 10.1002/jmv.21221 18649345 Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection Kao JH Chen PJ Lai MY Chen DS J Med Virol 2002 68 216 20 10.1002/jmv.10188 12210410 Influence of HBV gene heterogeneity on the failure of immunization with HBV vaccines in eastern China Liu SL Dong Y Zhang L Li MW Wo JE Lu LW Chen ZJ Wang YZ Ruan B Arch Virol 2009 154 437 43 10.1007/s00705-009-0315-y 19212700 Two HBV DNA+/HBsAg- blood donors identified by HBV NAT in Shenzhen, China Shang G Yan Y Yang B Shao C Wang F Li Q Seed CR Transfus Apher Sci 2009 4 3 7 10.1016/j.transci.2009.05.001 New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays Jongerius JM Wester M Cuypers HT van Oostendorp WR Lelie PN Poel van der CL van Leeuwen EF Transfusion 1998 38 56 9 10.1046/j.1537-2995.1998.38198141499.x 9482395 The clinical significance of surface antigen variants of hepatitis B virus Carman WF J Viral Hepat 1997 4 Suppl 1 11 20 10.1111/j.1365-2893.1997.tb00155.x 9097273 Mutants of the hepatitis B virus surface antigen that define some antigenically essential residues in the immunodominant a region Ashton-Rickardt PG Murray K J Med Virol 1989 29 196 203 10.1002/jmv.1890290310 2693610 Serologic and molecular profile of anti-HBc-positive blood bank donors in an area of low endemicity for HBV Kupski C Trasel FR Mazzoleni F Winckler MA Bender AL Machado DC Schmitt VM Dig Dis Sci 2008 53 1370 4 10.1007/s10620-007-0019-7 17932764 Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers Hou J Wang Z Cheng J Lin Y Lau GK Sun J Zhou F Waters J Karayiannis P Luo K Hepatology 2001 34 1027 34 10.1053/jhep.2001.28708 11679975 Occult hepatitis B virus infection: implications in transfusion Allain JP Vox Sang 2004 86 83 91 10.1111/j.0042-9007.2004.00406.x 15023176 Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay Chevrier MC St-Louis M Perreault J Caron B Castilloux C Laroche J Delage G Transfusion 2007 47 1794 802 10.1111/j.1537-2995.2007.01394.x 17880603 Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT Brojer E Grabarczyk P Liszewski G Mikulska M Allain JP Letowska M Hepatology 2006 44 1666 74 10.1002/hep.21413 17133474 Altered antigenicities of hepatitis B virus surface antigen carrying mutations outside the common "a" determinant Chen WN Oon CJ Toh I Am J Gastroenterol 2000 95 1098 9 10763979 Hepatitis B - a review of the role of NAT in enhancing blood safety Lelie N Heaton A J Clin Virol 2006 36 Suppl 1 S1 2 10.1016/S1386-6532(06)80001-6 16831686 Molecular characterization of occult hepatitis B cases in Greek blood donors Katsoulidou A Paraskevis D Magiorkinis E Moschidis Z Haida C Hatzitheodorou E Varaklioti A Karafoulidou A Hatzitaki M Kavallierou L Mouzaki A Andrioti E Veneti C Kaperoni A Zervou E Politis C Hatzakis A J Med Virol 2009 81 815 25 10.1002/jmv.21499 19319945 CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice Thompson JD Higgins DG Gibson TJ Nucleic Acids Res 1994 22 4673 80 10.1093/nar/22.22.4673 308517 7984417 Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Busch MP Transfus Clin Biol 2004 11 26 32 10.1016/j.tracli.2003.12.003 14980546 Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay Sato S Ohhashi W Ihara H Sakaya S Kato T Ikeda H Transfusion 2001 41 1107 13 10.1046/j.1537-2995.2001.41091107.x 11552066 HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA Yoshikawa A Gotanda Y Itabashi M Minegishi K Kanemitsu K Nishioka K Vox Sang 2005 88 77 86 10.1111/j.1423-0410.2005.00602.x 15720604 Efficacy of HBV NAT of pooled donor samples Sato S Ohhashi W Ihara H Sakaya S Kato T Ikeda H Transfusion 2002 42 660 10.1046/j.1537-2995.2002.00142.x 12084178 Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes Okamoto H Tsuda F Sakugawa H Sastrosoewignjo RI Imai M Miyakawa Y Mayumi M J Gen Virol 1988 69 Pt 10 2575 83 10.1099/0022-1317-69-10-2575 3171552 Hepatitis B virus (HBV) genotype determination by the COBAS AmpliPrep/COBAS TaqMan HBV Test, v2 Goedel S Rullkoetter M Weisshaar S Mietag C Leying H Boehl F J Clin Virol 2009 45 232 6 10.1016/j.jcv.2009.05.021 19535286 Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus Kiesslich D Crispim MA Santos C Ferreira Fde L Fraiji NA Komninakis SV Diaz RS J Infect Dis 2009 199 1608 11 10.1086/598955 19388852 Characteristics of circulating T cell receptor gamma-delta T cells from individuals chronically infected with hepatitis B virus (HBV): an association between V(delta)2 subtype and chronic HBV infection Chen M Zhang D Zhen W Shi Q Liu Y Ling N Peng M Tang K Hu P Hu H Ren H J Infect Dis 2008 198 1643 50 10.1086/593065 18954265 The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients Tsai MC Chen CH Lee CM Chen YT Chien YS Hung CH Wang JH Lu SN Yen YH Changchien CS Hu TH J Hepatol 2009 50 281 8 10.1016/j.jhep.2008.09.013 19070392 HBV genotype characterization and distribution in patients with HBV-related liver diseases in Zhejiang Province, P.R. China: possible association of co-infection with disease prevalence and severity Zumbika E Ruan B Xu CH Ni Q Hou W Chen Z Liu KZ Hepatobiliary Pancreat Dis Int 2005 4 535 43 16286258 Italian blood donors with anti-HBc and occult hepatitis B virus infection Manzini P Girotto M Borsotti R Giachino O Guaschino R Lanteri M Testa D Ghiazza P Vacchini M Danielle F Pizzi A Valpreda C Castagno F Curti F Magistroni P Abate ML Smedile A Rizzetto M Haematologica 2007 92 1664 70 10.3324/haematol.11224 18055990 Anti-hepatits B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice Bhatti FA Ullah Z Salamat N Ayub M Ghani E Transfusion 2007 47 74 9 10.1111/j.1537-2995.2007.01066.x 17207233 Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program Satake M Taira R Yugi H Hino S Kanemitsu K Ikeda H Tadokoro K Transfusion 2007 47 1197 205 10.1111/j.1537-2995.2007.01276.x 17581154 Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus Gerlich WH Glebe D Schuttler CG J Viral Hepat 2007 14 Suppl 1 16 21 10.1111/j.1365-2893.2007.00912.x 17958638 Identifying dramatic selection shifts in phylogenetic trees Dorman KS BMC Evol Biol 2007 7 Suppl 1 S10 10.1186/1471-2148-7-S1-S10 1796604 17288568 A revised evolutionary history of hepatitis B virus (HBV) Fares MA Holmes EC J Mol Evol 2002 54 807 14 10.1007/s00239-001-0084-z 12029362 The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection Kawabe N Hashimoto S Harata M Nitta Y Murao M Nakano T Shimazaki H Arima Y Komura N Kobayashi K Yoshioka K J Gastroenterol 2009 44 751 6 10.1007/s00535-009-0061-7 19430716 Quantitative detection of the M204V HBV minor variants by amplification refractory mutation system real-time polymerase chain reaction (ARMS rt-PCR) combined with molecular beacon Ntziora F Paraskevis D Haida C Magiorkinis E Manesis E Papatheodoridis G Manolakopoulos S Beloukas A Chryssoy S Magiorkinis G Sypsa V Hatzakis A J Clin Microbiol 2009 47 2544 50 10.1128/JCM.00045-09 19553583 A new intertype recombinant between genotypes C and D of hepatitis B virus identified in China Wang Z Liu Z Zeng G Wen S Qi Y Ma S Naoumov NV Hou J J Gen Virol 2005 86 985 90 10.1099/vir.0.80771-0 15784891 Identification of Hepatitis B virus putative intergenotype recombinants by using fragment typing Yang J Xing K Deng R Wang J Wang X J Gen Virol 2006 87 2203 15 10.1099/vir.0.81752-0 16847116